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Abstract 
Clinical outcome of postchemotherapy retroperitoneal lymph node dissection in advanced 
nonseminomatous germ cell tumors 
Johan Andersson. Degree project, Programme in Medicine 
Department of Urology, Institution of Clinical Sciences, Sahlgrenska Academy, University of 
Gothenburg  
Background: Nonseminomatous germ cell tumors (NSGCT) which have not responded 
adequately to chemotherapy requires subsequent surgical removal of the residual tumor (post 
chemotherapy retroperitoneal lymph node dissection, PC-RPLND). 
Following PC-RPLND about 40% of the patients present fibrosis/necrosis in the final 
pathology report. Yet no truly satisfactory model is available to select patients where PC-
RPLND treatment would improve prognosis.  
Objectives: To evaluate perioperative and long-term clinical outcome of PC-RPLNDs 
performed between 2004-01-01 and 2017-12-13 at Sahlgrenska University Hospital and to 
analyze predicting factors for final pathology. 
Methods: A retrospective analysis was made on patients who underwent PC-RPLND at 
Sahlgrenska University Hospital between the years 2004 and 2017. χ² test was used to analyze 
associations between tumor shrinkage and final pathology results.  
Results: A total of 114 procedures were performed of which 85 were eligible for analysis. 
After a median follow up time of 6.8 years, 81 (95.3%) patients were alive. A total of 4 
(4.7%) patients had died, 3 (3.5%) of which due to NSGCT. Regarding the safety of the 
procedure, 5 (5.9%) patients experienced complication grade IIIa (Clavien-Dindo 
classification). Six (7.1%) patients suffered from relapse of which 3 (3.5%) subsequently died 
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as mentioned above. In the final pathology report, 37 (43.5%) displayed fibrosis/necrosis 40 
(47.1%) teratoma and 8 (9.4%) viable cancer. Tumor shrinkage of ≥50% was associated with 
fibrosis/necrosis at PC-RPLND. 
Conclusions: Perioperative complications were low, with only 5 Clavien-Dindo IIIa 
complications. With greater shrinkage levels after chemotherapy, the probability of finding 
fibrosis/necrosis in the residual mass increased. However, a substantial proportion of patients 
with the greatest tumor size decrease would still benefit from the procedure.  
Keywords: Nonseminomatous germ cell tumour; Retroperitoneal lymph node dissection; 
Testicular cancer 
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Background 
Testicular cancer (TC) is a rare form of malignancy constituting about 1% of all cancers. 
Nevertheless, it is the most common malignancy among men aged 15-35 years. 
Approximately 380 cases of testicular cancer are diagnosed each year in Sweden (1). The 
incidence of TC has doubled worldwide in white men during the last 40 years with an annual 
increase of 3% to 6% (2, 3). In the Nordic countries this increase is even greater. In Sweden 
the incidence has increased from about 3/100 000/year in 1970 to about 8/100 000/year in 
2015, and in Norway it has more than tripled during the same time period (4, 5). The cause of 
this increase in not known.  
TC can be divided into two major groups: tumors originating from germ cells and tumors 
developing from the gonadal stroma such as the Sertoli or the Leydig cells. Germ cell tumors 
make up the majority (95%) and can be further divided into seminomas, embryonal 
carcinoma, yolk sac tumor, chorioncarcinoma, teratoma or mixed tumors (6). Yet another 
dichotomy is made between pure seminomas and nonseminomatous germ cell tumors 
(NSGCT). If the tumor consists of anything other than seminoma it is considered a NSGCT. 
The groups differ in histopathologic features and the fact that pure seminomas have normal 
levels of alphafetoprotein (AFP) in contrast to NSGCT. In addition, the two groups differ in 
prognosis and treatment regimens. Radiation therapy has been preferred historically for pure 
seminomas and chemotherapy for NSGCT. However, due to the risk of cardiovascular 
decease and secondary cancers chemotherapy has become the preferred treatment for 
seminomas as well(7, 8). 
About 50 % of patients diagnosed with NSGCT will have clinically detectable metastases at 
diagnosis. Yet about one third of the patients in the group without clinically detectable 
metastases will reveal metastases during the 6 week long surveillance period (6). 
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The most common metastatic site for NSGCT is lymph nodes in the retroperitoneum. This is 
due to the testes “path of descent” from the superior posterior fetal abdomen through the 
inguinal canal and into the scrotum. When spread hematogenous the most common site of 
visceral metastases is the lungs (9).  
 
The most common symptom a TC patient presents with is a palpable resistance in one of the 
testicles. This is sometimes accompanied by scrotal pain but more often than not the pain is 
absent. Through ultrasound the diagnosis is either to confirmed or ruled out. If diagnosis is 
confirmed a subsequent unilateral radical orchiectomy of the afflicted testicle is performed.  It 
is important that the procedure is radical i.e. that the spermatic cord is also removed. The 
spermatic cord sometimes houses potentially malignant cells therefor the removal of this 
structure reduces the risk of relapse. The procedure is done through an incision in the inguinal 
region where subsequently the testicle and spermatic cord are evacuated. 
 
After a diagnosis is confirmed a clinical staging will ensue. The model most commonly used 
are Royal Marsden which consists of 4 stages. The clinical staging procedure includes: serum 
levels of AFP, β-HCG, LDH and CT of thorax, abdomen and pelvis with IV and oral contrast. 
Clinical stage (CS) I shows no evidence of metastases.  
In CS II patients have metastatic disease restricted to abdominal nodes. This stage will hold 
the majority of patients. This is due to the testes “path of descent” from the superior posterior 
fetal abdomen through the inguinal canal and into the scrotum. Therefore, the most common 
site for NSGCT to metastasize is lymph nodes in the retroperitoneum.  
In CS III patients have supradiaphragmatic node involvement.  
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CS IV is the most advanced stage and these patients present with extra-lymphatic metastases. 
When spread hematogenous the most common site of visceral metastases is the lungs (9). 
About 50 % of patients diagnosed with NSGCT will have clinically detectable metastases at 
diagnosis. If a patient is at CS I a later definitive staging is performed 6-8 weeks after 
orchiectomy. This is due about one third of the patients in the group without clinically 
detectable metastases will reveal metastases during the 6 week long surveillance period (6). 
 
As mentioned earlier the primary treatment of metastatic NSGCT is cisplatin-based 
chemotherapy. In the 1970’s this new drug revolutionized the treatment of TC with radically 
improved prognoses. Prior to the cisplatin era the outlook for patients with TC was very 
bleak. The response to the chemotherapy is evaluated radiologically and by repeated tumor 
marker measurements. Although cure rates are remarkably high following this treatment, 
surgical removal of residual tumor is sometimes required. If the residual tumor is situated 
within the retroperitoneal space a post chemotherapy retroperitoneal lymph node dissection 
(PC-RPLND) is performed.  
 
Open PC-RPLND is extensive and requires a large incision and can be associated with 
significant morbidity.  To limit the scale the surgeon focuses on specific areas of the 
retroperitoneum. These areas are determined by patterns of dissemination, the laterality of the 
primary testis tumor and radiological findings showing the extent of the disease. 
The number of PC-RPLNDs performed in Sweden each year is approximately 35-40 (Figure 
1) 
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Figure 1. Flowchart over the approximate number people diagnosed with TC that ultimately 
goes through PC-RPLND in Sweden each year(10). 
 
The figure below displays the different areas commonly used by surgeons. Anatomical 
landmarks such as the renal vessels, aorta, vena cava and arteria mesenterica inferior are used 
to determine the different areas (Figure 2). 
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Figure 2. Schematic picture of the different areas of evacuation in retroperitoneal lymph node 
dissection.  
 
These areas are then combined into certain templates. For example, the left unilateral template 
consists of areas 2+3+6+8+10 and the right 1+2+3+4+5+7+9. The right unilateral template is 
more comprehensible due to the path of the descending testes during development. Areas 11 
and 12 are only occasionally evacuated.   
 
Previous studies have shown that a substantial portion of patients, 35-50%, will have 
necrosis/fibrosis in the resected specimen following PC-RPLND. About 35-60% will have 
teratoma and only 2-15% will have viable cancer (11-14). Since necrosis/fibrosis is benign 
these patients do not benefit clinically from the procedure. Moreover, the proportion that 
reveals viable cancer is slowly dropping as better chemotherapy regimes continues to develop 
(6). Yet no truly satisfactory model is at hand for the selection of patients where PC-RPLND 
treatment would improve prognosis. 
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Teratomas are generally seen as a benign entity and does not frequently metastasize. 
However, they can grow in size and the mass can cause problems locally. Furthermore, there 
is a small risk of malignant transformation (2.9%) although rare (15). 
A number of predictors for necrosis/fibrosis in the final pathology report has been identified. 
These include primary tumor histology, prechemotherapy AFP, prechemotherapy human 
chorionic gonadotropin (HCG), prechemotherapy lactate dehydrogenase (LDH), mass size 
and reduction in size (12).Other factors that have been suggested is the appearance of 
choriocarcinoma and absence of teratoma in the orchiectomy pathology report (16). 
SWENOTECA (Swedish and Norwegian Testicular Cancer Group) changed their guidelines 
for the procedure with the release of SWENOTECA VIII in May 2012. Prior to this change 
every patient who initially had abdominal lymph nodes >2 cm before chemotherapy 
underwent the procedure irrespective of size of residual mass. The current guidelines state 
that the procedure is only mandatory for those with a residual mass of ≥10 mm after 
chemotherapy.  
 
Being a technically demanding, and relatively infrequent procedure, PC-RPLND should be 
performed by experienced surgeons in dedicated referral center. Since 2017, Sahlgrenska 
University Hospital is one of two Swedish treatment centers for PC-RPLND.  
 
Aim 
To evaluate perioperative and long-term clinical outcome of PC-RPLNDs performed between 
2004-01-01 and 2017-12-31 at Sahlgrenska University Hospital and to analyze predicting 
factors for final pathology.  
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Method 
A retrospective analysis was made on all patients who underwent PC-RPLND due to 
advanced NSGCT at Sahlgrenska University Hospital during 2004-01-01 through 2017-12-
31. The procedures were identified via the Sahlgrenska surgical database. Patient and tumor 
characteristics (age, testicular tumor pathology, laterality, tumor marker status, clinical stage 
and IGCCCG group) were gathered from medical records. Perioperative data (operation time, 
hospital stay, abdominal drainage, surgical complications, and any additional surgical 
procedures) as well as long-term clinical outcome (relapse and mortality) were registered. 
Surgical complications were classified according to the Clavien-Dindo system (17). In 
accordance with current guidelines, extent of retroperitoneal masses was evaluated based on 
appearance on CT, with the greatest transverse diameter as the size estimate. Post-chemo 
residual masses were classified into 5 size groups (<10mm, 10-<20mm, 20-<50mm, 50-
<100mm and ≥100mm), and 3 groups based therapeutic response to chemotherapy 
(progression, shrinkage <50% and shrinkage ≥50%). Final pathology of RPLND specimen 
were classified as necrosis/fibrosis, teratoma or viable cancer.  
We used the statistic tool SPSS to perform descriptive and inferential analyses. The χ² test 
was used to explore relationships between tumor shrinkage and necrosis/fibrosis in final 
pathology. 
 
Ethics 
Approval for the data collection has been given by the head of the urology department. 
National identification number and information regarding the patients have been handled in 
accordance to laws and regulations. The individuals were made unidentifiable upon analysis 
outside the Sahlgrenska server. 
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Results 
Patient and tumor characteristics 
During the 14-year study period, a total of 114 RPLNDs, on 109 men, were performed. Of 
those, 5 were lumpectomies due to seminoma metastases, 13 had not received prior 
chemotherapy, 6 had other NSGCT malignancies in the final RPLND pathology report, and 5 
had missing data, leaving 85 procedures and patients eligible for analysis. The median follow 
up time was 6.8 years with an interquartile range (IQR) of 1,7-10,9. Median age at time of 
RPLND was 27 years (IQR 23-34).  Further details are shown in Table 1 below. 
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At diagnosis, the majority of patients (55.3%) were at stage 2 (metastatic disease restricted to 
abdominal nodes). About one third (36.7%) were at stage 4 (extra lymphatic mestastases in 
i.e. brain, liver or bone). Four patients had no evidence of metastases (stage 1) but eventually 
revealed a mass on CT scan during surveillance.  
In 4 cases only seminomatous cells could be found in the primary histology report. But due to 
elevated tumor markers these were treated as NSGCT. 
 
Perioperative parameters 
The perioperative parameters are shown in Table 2. Less than one third (29%) of the patients 
received a drain at the end of the procedure. However, four patients needed drain insertion 
sometime after the main surgery due to signs of lymph leakage. Totally 5 (5.9%) patients 
(including those who had a drain after surgery) suffered from severe complications (class IIIa 
according to Clavien-Dindo classification), no patient having higher grades. Other associated 
interventions during RPLND were rare; in one case a combined unilateral nephrectomy and 
adrenalectomy was performed to ensure radicality. In two cases the ureter was sutured and in 
one case the bladder was repaired due to iatrogenic injury. Other minor associated 
interventions are shown in Table 2.  
The operation time had a median of 184 min (IQR 152-229). Postoperative stay had a median 
of 7 days (IQR 6-8). The median blood loss during the operation was 500 ml (IQR 300-100) 
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Tumor characteristics 
Table 3 shows the distribution of tumor size change, residual tumor size and final RPLND 
pathology result. 
 
In the final RPLND pathology analysis of the tumor, 37 (43.5%) had benign tissue, 40 
(47.1%) had teratoma, and 8 (9.4%). had viable cancer. Figure 3 shows the distribution of 
final histology depending on therapeutic response to chemotherapy. With greater shrinkage 
came an increase in the portion of necrosis/fibrosis and a decrease in the portion of viable 
cancer. 
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Figure 4 shows the distribution of final histology depending on size of residual mass. It shows 
that no viable cancer was found in the group that had a residual tumor mass of less than 10 
mm. 
Figure 3. Distribution of Retroperitoneal Lymph 
Node Dissection (RPLND) pathology result in 
relation to tumor size change 
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Through χ² analysis we found that a tumor shrinkage of ≥50% was associated with 
necrosis/fibrosis at PC-RPLND (p<0.005) 
 
Clinical outcome 
Up until 2017-12-31, 95.3% of the patients were alive at end of follow-up. Only 4 were 
deceased, 3 of which as a result of NSGCT yielding a 3.5% disease-specific mortality at 6.8 
years. Those who died due to NSGCT did so within one year after the time of surgery, 5, 10 
and 11 months respectively. These three patients displayed necrosis/fibrosis, viable cancer 
and mature teratoma in the final RPLND pathology report respectively. All patients were 
diagnosed at stage 4 (Extra-lymphatic metastases) and had poor prognosis according to 
IGCCCG.  
Figure 4. Distribution of Retroperitoneal 
Lymph Node Dissection (RPLND) pathology 
result in relation to residual tumor size 
16 
 
An additional three patients had nonfatal cancer recurrence during follow-up leaving 6 (7.1%) 
with recurrence in total. Of these three patients two had mature teratoma and one had 
necrosis/fibrosis in their final RPLND pathology report after the first procedure. All three 
patients underwent subsequent surgery (resection of residual mass/lumpectomy) and were 
alive at the end of the study period. 
 
Discussion 
According to current guidelines on TC, patients with residual masses ≥1 cm after 
chemotherapy for NSGCT should undergo PC-RPLND due to the risk of teratoma or viable 
cancer in the resected specimen. In this study, the risk of teratoma was 47% and viable cancer 
9%, which is in line with previous studies (11, 18, 19). The remaining 44% revealed benign 
histology meaning that a substantial portion of patients underwent the procedure without a 
clinical benefit. However, 59 of the 85 patients in this study were treated before May 2012, 
when SWENOTECA (Swedish and Norwegian Testicular Cancer Group) changed the 
indication for the procedure to only be mandatory for those with a residual mass of ≥10 mm. 
A total of 15 patients with a residual mass of <10 mm underwent the procedure, none of 
which had viable cancer in the final pathology report. Of these 15 patients 7 presented with 
teratoma and 8 with necrosis/fibrosis. This supports the most recent SWENOTECA 
guidelines from May 2012. Hence, the indication for PC-RPLND has sharpened over the 
years, but still a significant portion of TC patients need to undergo extensive surgery with no 
benefit. 
While awaiting further diagnostic and molecular models to better predict final histology we 
need to minimize the risk of complications and negative effects of treatment. In November 
2017, RPLND for metastatic TC was centralized to two national centers in Sweden in an 
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attempt to improve the quality of this relatively rare procedure. In addition, minimally 
invasive techniques have evolved and in the present study two patients were operated robot 
assisted laparoscopically. With a low rate of complications (5.9% Clavien-Dindo grade IIIa 
complications and no grade IIIb or above) and a 92.9% disease free survival this study 
supports previous reports from high-volume centers. These indicate that RPLND after 
primary chemotherapy for advanced NSGCT is safe and results in long-term disease-free 
survival. 
In line with previous reports we found that a greater shrinkage levels after chemotherapy 
increased the probability of finding necrosis/fibrosis in the final RPLND histology. However, 
a substantial proportion of patients with the greatest decrease (≥50%) in tumor size would still 
benefit from the procedure (2 with viable cancer and 12 with teratoma out of 41).  
Due to lack of time no further inferential analysis were made. But even though the χ² analysis 
is rudimentary it shows an important statistical relationship.   
 
In recent years the overtreatment of this patient group has sparked an interest among 
clinicians and researchers to come up with better models for the selection of these patients 
(20, 21). By identifying determining factors and applying appropriate models there is a hope 
to change the paradigm of advanced testicular cancer treatment and avoid 
unnecessary retroperitoneal lymph node dissection. 
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Populärvetenskaplig sammanfattning på svenska 
Testikelcancer är en sällsynt sjukdom som utgör ca 1% av all cancer. Den är emellertid den 
vanligaste typen av cancer bland män i åldern 15–35 år. Antalet som drabbas av sjukdomen 
har dubblerats världen över, och nästan tredubblats i Sverige, under de senaste 40 åren. Vad 
orsaken till denna ökning beror på vet man inte. 
Det finns olika flera typer av testikelcancer. Den typ vi har studerat kallas icke-seminomatös 
och är den vanligaste, den utgör ca hälften av fallen. Sjukdomen sprider sig vanligtvis till 
lymfkörtlarna i rummet bakom bukhålan och den primära behandlingen är cellgifter. Även om 
de allra flesta blir friska efter cellgiftsbehandlingen krävs ibland operation för att avlägsna 
kvarvarande tumörmassa.  
Efter utrymningen skickas den borttagna vävnaden till analys. I cirka 40% av fallen visar det 
sig att vävnaden bara består av ärrvävnad, dött material eller annan godartad vävnad. För 
dessa patienter är alltså operationen onödig. Än så länge finns det ingen tillfredsställande 
modell för att välja ut patienter där ingreppet är nödvändigt och förbättrar prognosen. 
Vi gick igenom medicinska journaler och fann 85 lämpliga operationer att analysera som 
utförts på Sahlgrenska sjukhus mellan åren 2004 och 2017.  Det vi var intresserade av att veta 
var hur det gick för dessa patienter både på kort och lång sikt. Vi ville även analysera faktorer 
som skulle kunna förutsäga om operationen var nödvändig eller ej. 
Uppföljningstiden av patienterna var i genomsnitt ca 7 år. Fem patienter drabbades av 
allvarligare komplikationer i samband med operationen och sammanlagt fick 6 patienter 
återfall i sin cancer, varav 3 avled och 3 överlevde. 
I den slutliga analysen av tumören hade 37 godartad vävnad, 40 hade teratom (som oftast är 
en godartad tumör) och 8 hade kvarvarande cancer. 
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Med tanke på ingreppets omfattning får komplikationerna, endast 5 allvarligare, i anslutning 
till operationen i denna studie anses vara låg. Även återfall och efterföljande död på grund av 
sin testikelcancer (6 respektive 3) var få till antalet. 
Vi fann ingen kvarvarande cancer hos patienter som genomgick ingreppet och hade en 
återstående tumörmassa på mindre än 10 mm. Detta stödjer de senaste riktlinjerna från 
SWENOTECA (Swedish and Norwegian Testicular Cancer Group) från 2012. Då ändrade 
man sig och ansåg att utrymning endast vara obligatorisk för personer med en återstående 
massa på mer eller lika med 10 mm. Före detta skulle varje patient som hade förstorade 
lymfkörtlar före kemoterapibehandlingen genomgå operationen. 
Vi fann också genom statistiska analyser att med större krympningsnivåer efter 
kemoterapibehandlingen ökar sannolikheten för att hitta godartad vävnad i restmassan. Dock 
är det emellertid så att en stor del av patienterna i gruppen med den största minskningen av 
tumörstorleken fortfarande drar nytta av utrymningen. 
Fortsatt forskning inom området är nödvändigt. Skulle man kunna hitta en krympningsgräns 
kombinerat med andra faktorer där man kan avstå operation utan att man missar någon med 
kvarvarande cancer? Det behövs göras mycket för att förbättra urvalet av patienter och på så 
sätt slippa onödiga och dyra operationer samt minska onödigt mänskligt lidande. 
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